{
    "2021-10-13": [
        [
            {
                "time": "2023-10-24",
                "original_text": "FDA Approves VerzenioÂ® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approves",
                        "Verzenio",
                        "abemaciclib",
                        "CDK4/6",
                        "Inhibitor",
                        "HR+",
                        "HER2-",
                        "Breast Cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}